Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Review Article

Therapeutical Approach to Arterial Hypertension - Current State of the Art

Author(s): Milica Radosavljevic, Danijela Vučević, Janko Samardžić, Miroslav Radenkovic and Tatjana Radosavljević*

Volume 31, Issue 29, 2024

Published on: 31 January, 2024

Page: [4602 - 4620] Pages: 19

DOI: 10.2174/0109298673274823231220063652

Price: $65

Open Access Journals Promotions 2
conference banner
Abstract

Arterial hypertension (AH) is recognized as the most common illness within the group of cardiovascular diseases and the most massive chronic non-infectious disease in the world. The number of hypertensive patients worldwide has reached 1.28 billion, contributing to an increase in cardiovascular diseases and premature death globally. The high prevalence of hypertension emphasizes the importance of effectively treating this condition. Elevated blood pressure often leads to lethal complications (heart failure, stroke, renal disorders, etc.) if left untreated. Considering an increase in AH prevalence in the future, a successful therapeutical approach to this disease and its complications is essential. The goal of AH treatment is to maintain normotensive blood pressure through various approaches, including lifestyle changes, a well-balanced diet, increased physical activity, psychoeducation, and, when necessary, pharmacotherapy. The evolving pharmacotherapeutic landscape reflects the progress made in our understanding of hypertension and emphasizes the need for continuous innovation to meet the challenges posed by this prevalent global health concern. The journey toward more effective and tailored treatments for hypertension is ongoing, and the introduction of new medications plays a pivotal role in shaping the future of antihypertensive pharmacotherapy.

Keywords: Arterial hypertension, exacerbating factors, resistant hypertension, nonpharmacologic treatment, pharmacotherapy, hypertensive crisis.

« Previous Next »
[1]
Nenezic, N.; Matunovic, R.; Gudelj, O.; Djuric, I.; Jancic, J.; Samardzic, J. Stress and arterial hypertension - from pathophysiology to pharmacology. Srp. Arh. Celok. Lek., 2021, 149(11-12), 737-740.
[http://dx.doi.org/10.2298/SARH210323066N]
[2]
World health organization. hypertension. 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/hypertension (Accessed 2023-07-13).
[3]
Sutters, M. Overview: Systemic hypertension. In: In Current Medical Diagnosis and Treatment; Papadakis, M.; McPhee, S.; Rabow, M.; McQuaid, K., Eds.; McGraw-Hill Education: Columbus, OH, 2023; pp. 443-474.
[4]
Vučević, D.; Radak, Đ.; Đorđević, D.; Miletić, M.; Jakovljević, A.; Jorgačević, B.; Vesković, M. Chronic low grade inflammation in aging process as a link on a chain of obesity - related vascular disorders. Medicinska istraživanja, 2018, 52(1), 32-42.
[5]
Akhtar, S.; Rosenbaum, S.; Akhtar, S.; Rosenbaum, S. Principles of Geriatric Critical Care; Akhtar, S.; Rosenbaum, S., Eds.; Cambridge University Press: Cambridge, England, 2018.
[http://dx.doi.org/10.1017/9781316676325]
[6]
Pauldine, R. Geriatric cardiovascular critical care. In: In Principles of Geriatric Critical Care; Shamsuddin, A.; Stanley, R., Eds.; Cambridge University Press: Cambridge, England, 2018; pp. 81-101.
[http://dx.doi.org/10.1017/9781316676325.007]
[7]
Greenland, P.; Peterson, E. The New 2017 ACC/AHA guidelines “up the pressure” on diagnosis and treatment of hypertension. JAMA, 2017, 318(21), 2083-2084.
[http://dx.doi.org/10.1001/jama.2017.18605] [PMID: 29159417]
[8]
Leung, A.A.; Daskalopoulou, S.S.; Dasgupta, K.; McBrien, K.; Butalia, S.; Zarnke, K.B.; Nerenberg, K.; Harris, K.C.; Nakhla, M.; Cloutier, L.; Gelfer, M.; Lamarre-Cliche, M.; Milot, A.; Bolli, P.; Tremblay, G.; McLean, D.; Tobe, S.W.; Ruzicka, M.; Burns, K.D.; Vallée, M.; Prasad, G.V.R.; Gryn, S.E.; Feldman, R.D.; Selby, P.; Pipe, A.; Schiffrin, E.L.; McFarlane, P.A.; Oh, P.; Hegele, R.A.; Khara, M.; Wilson, T.W.; Penner, S.B.; Burgess, E.; Sivapalan, P.; Herman, R.J.; Bacon, S.L.; Rabkin, S.W.; Gilbert, R.E.; Campbell, T.S.; Grover, S.; Honos, G.; Lindsay, P.; Hill, M.D.; Coutts, S.B.; Gubitz, G.; Campbell, N.R.C.; Moe, G.W.; Howlett, J.G.; Boulanger, J-M.; Prebtani, A.; Kline, G.; Leiter, L.A.; Jones, C.; Côté, A-M.; Woo, V.; Kaczorowski, J.; Trudeau, L.; Tsuyuki, R.T.; Hiremath, S.; Drouin, D.; Lavoie, K.L.; Hamet, P.; Grégoire, J.C.; Lewanczuk, R.; Dresser, G.K.; Sharma, M.; Reid, D.; Lear, S.A.; Moullec, G.; Gupta, M.; Magee, L.A.; Logan, A.G.; Dionne, J.; Fournier, A.; Benoit, G.; Feber, J.; Poirier, L.; Padwal, R.S.; Rabi, D.M.; Rabi, D.M. Hypertension Canada’s 2017 guidelines for diagnosis, risk assessment, prevention, and treatment of hypertension in adults. Can. J. Cardiol., 2017, 33(5), 557-576.
[http://dx.doi.org/10.1016/j.cjca.2017.03.005] [PMID: 28449828]
[9]
Jin, J. Checking blood pressure at home. JAMA, 2017, 318(3), 310.
[http://dx.doi.org/10.1001/jama.2017.6670] [PMID: 28719694]
[10]
Melville, S.; Byrd, J.B. Out-of-office blood pressure monitoring in 2018. JAMA, 2018, 320(17), 1805-1806.
[http://dx.doi.org/10.1001/jama.2018.14865] [PMID: 30398589]
[11]
Myers, M.G. Automated office blood pressure-incorporating sprint into clinical practice. Am. J. Hypertens., 2017, 30(1), 8-11.
[http://dx.doi.org/10.1093/ajh/hpw086] [PMID: 27551025]
[12]
Byrd, J.B.; Turcu, A.F.; Auchus, R.J. Primary aldosteronism. Circulation, 2018, 138(8), 823-835.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.033597] [PMID: 30359120]
[13]
Bangash, A.; Wajid, F.; Poolacherla, R.; Mim, F.K.; Rutkofsky, I.H. Obstructive sleep apnea and hypertension: A review of the relationship and pathogenic association. Cureus, 2020, 12(5), e8241.
[http://dx.doi.org/10.7759/cureus.8241] [PMID: 32582500]
[14]
Palmer, B.F.; Clegg, D.J. Blood pressure lowering and potassium intake. J. Hum. Hypertens., 2020, 34(10), 671-672.
[http://dx.doi.org/10.1038/s41371-020-00396-1] [PMID: 32788665]
[15]
Vučević, D.; Samardžić, J.; Radosavljević, M.; Radak, U.; Jorgačević, B.; Đorđević, D.; Kovačević, S. Unbalanced diet as a cardiometabolic risk factor. Medicinska istraživanja, 2022, 55(1), 23-34.
[16]
Radosavljevic, T.; Vučević, D. Binge drinking: pathophysiological and psychological aspects. In: Binge eating and binge drinking: psychological, social and medical implications; Harris, S.B., Ed.; Nova Science: New York, 2013; pp. 201-216.
[17]
Virdis, A.; Giannarelli, C.; Fritsch Neves, M.; Taddei, S.; Ghiadoni, L. Cigarette smoking and hypertension. Curr. Pharm. Des., 2010, 16(23), 2518-2525.
[http://dx.doi.org/10.2174/138161210792062920] [PMID: 20550499]
[18]
Herrmann, S.M.; Textor, S.C. Renovascular hypertension. Endocrinol. Metab. Clin. North Am., 2019, 48(4), 765-778.
[http://dx.doi.org/10.1016/j.ecl.2019.08.007] [PMID: 31655775]
[19]
Morgan, T.; Anderson, A. The effect of nonsteroidal anti-inflammatory drugs on blood pressure in patients treated with different antihypertensive drugs. J. Clin. Hypertens., 2003, 5(1), 53-57.
[http://dx.doi.org/10.1111/j.1524-6175.2003.00514.x] [PMID: 12556654]
[20]
Carpio-Rivera, E.; Moncada-Jiménez, J.; Salazar-Rojas, W.; Solera-Herrera, A. Acute effects of exercise on blood pressure: A meta-analytic investigation. Arq. Bras. Cardiol., 2016, 106(5), 422-433.
[http://dx.doi.org/10.5935/abc.20160064] [PMID: 27168471]
[21]
Smart, N.A.; Gow, J.; Bleile, B.; Van der Touw, T.; Pearson, M.J. An evidence-based analysis of managing hypertension with isometric resistance exercise-are the guidelines current? Hypertens. Res., 2020, 43(4), 249-254.
[http://dx.doi.org/10.1038/s41440-019-0360-1] [PMID: 31758166]
[22]
Liu, M.Y.; Li, N.; Li, W.A.; Khan, H. Association between psychosocial stress and hypertension: A systematic review and meta-analysis. Neurol. Res., 2017, 39(6), 573-580.
[http://dx.doi.org/10.1080/01616412.2017.1317904] [PMID: 28415916]
[23]
Vučević, D.; Jorgačević, B.; Radosavljević, M.; Đorđević, D.; Radak, Đ. Risk factors for atherosclerosis in the light of existing scientific facts. Medicinska Istraživanja, 2017, 51(3), 7-19.
[24]
Rimoldi, S.F.; Scherrer, U.; Messerli, F.H. Secondary arterial hypertension: when, who, and how to screen? Eur. Heart J., 2014, 35(19), 1245-1254.
[http://dx.doi.org/10.1093/eurheartj/eht534] [PMID: 24366917]
[25]
Vučević, D.; Jorgačević, B.; Radosavljević, T.; Radak, Đ.; Kovačević, D. The relationship between insulin resistance and cardiovascular system disorders. Medicinska Istraživanja, 2015, 49(3), 5-15.
[26]
Yildiz, M.; Oktay, A.A.; Stewart, M.H.; Milani, R.V.; Ventura, H.O.; Lavie, C.J. Left ventricular hypertrophy and hypertension. Prog. Cardiovasc. Dis., 2020, 63(1), 10-21.
[http://dx.doi.org/10.1016/j.pcad.2019.11.009] [PMID: 31759953]
[27]
Cordonnier, C.; Demchuk, A.; Ziai, W.; Anderson, C.S. Intracerebral haemorrhage: Current approaches to acute management. Lancet, 2018, 392(10154), 1257-1268.
[http://dx.doi.org/10.1016/S0140-6736(18)31878-6] [PMID: 30319113]
[28]
Supiano, M.A.; Williamson, J.D. New guidelines and sprint results. Circulation, 2019, 140(12), 976-978.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.119.037872] [PMID: 31525101]
[29]
Seccia, T.M.; Caroccia, B.; Calò, L.A. Hypertensive nephropathy. Moving from classic to emerging pathogenetic mechanisms. J. Hypertens., 2017, 35(2), 205-212.
[http://dx.doi.org/10.1097/HJH.0000000000001170] [PMID: 27782909]
[30]
Khoynezhad, A.; Plestis, K. A. Managing emergency hypertension in aortic dissection and aortic aneurysm surgery. J. Card. Surg, 2006, 21(1), 3-7.
[http://dx.doi.org/10.1111/j.1540-8191.2006.00213.x]
[31]
Radenković, M.; Stojanović, M.; Prostran, M. Novel facts in pharmacology of endothelial dysfunction. Medicinska Istraživanja, 2015, 49(3), 18-22.
[32]
Karakayali, M.; Omar, T.; Artac, I.; Rencuzogullari, İ.; Karabag, Y.; Demir, O. The relationship between the systemic immune-inflammation index and reverse-dipper circadian pattern in newly diagnosed hypertensive patients. J. Clin. Hypertens., 2023, 25(8), 700-707.
[http://dx.doi.org/10.1111/jch.14688] [PMID: 37464585]
[33]
Edvardsson, B. Hypertensive encephalopathy and cerebral infarction. Springerplus, 2014, 3(1), 741.
[http://dx.doi.org/10.1186/2193-1801-3-741] [PMID: 25932363]
[34]
Zuber, S.M.; Kantorovich, V.; Pacak, K. Hypertension in pheochromocytoma: Characteristics and treatment. Endocrinol. Metab. Clin. North Am., 2011, 40(2), 295-311.
[http://dx.doi.org/10.1016/j.ecl.2011.02.002] [PMID: 21565668]
[35]
Fu, J.; Liu, Y.; Zhang, L.; Zhou, L.; Li, D.; Quan, H.; Zhu, L.; Hu, F.; Li, X.; Meng, S.; Yan, R.; Zhao, S.; Onwuka, J.U.; Yang, B.; Sun, D.; Zhao, Y. Nonpharmacologic interventions for reducing blood pressure in adults with prehypertension to established hypertension. J. Am. Heart Assoc., 2020, 9(19), e016804.
[http://dx.doi.org/10.1161/JAHA.120.016804] [PMID: 32975166]
[36]
Kaminsky, L.A.; German, C.; Imboden, M.; Ozemek, C.; Peterman, J.E.; Brubaker, P.H. The importance of healthy lifestyle behaviors in the prevention of cardiovascular disease. Prog. Cardiovasc. Dis., 2022, 70, 8-15.
[http://dx.doi.org/10.1016/j.pcad.2021.12.001] [PMID: 34922952]
[37]
Mattavelli, E.; Catapano, A.L.; Baragetti, A. Molecular immune-inflammatory connections between dietary fats and atherosclerotic cardiovascular disease: Which translation into clinics? Nutrients, 2021, 13(11), 3768.
[http://dx.doi.org/10.3390/nu13113768] [PMID: 34836026]
[38]
Dan, X.; Mushi, Z.; Baili, W.; Han, L.; Enqi, W.; Huanhu, Z.; Shuchun, L. Differential analysis of hypertension-associated intestinal microbiota. Int. J. Med. Sci., 2019, 16(6), 872-881.
[http://dx.doi.org/10.7150/ijms.29322] [PMID: 31337961]
[39]
Sidhu, S.K.; Weavil, J.C.; Rossman, M.J.; Jessop, J.E.; Bledsoe, A.D.; Buys, M.J.; Supiano, M.S.; Richardson, R.S.; Amann, M. Exercise pressor reflex contributes to the cardiovascular abnormalities characterizing. Hypertension, 2019, 74(6), 1468-1475.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.119.13366] [PMID: 31607174]
[40]
Williams, B.; Mancia, G.; Spiering, W.; Agabiti Rosei, E.; Azizi, M.; Burnier, M.; Clement, D.; Coca, A.; De Simone, G.; Dominiczak, A.; Kahan, T.; Mahfoud, F.; Redon, J.; Ruilope, L.; Zanchetti, A.; Kerins, M.; Kjeldsen, S.; Kreutz, R.; Laurent, S.; Lip, G.Y.H.; McManus, R.; Narkiewicz, K.; Ruschitzka, F.; Schmieder, R.; Shlyakhto, E.; Tsioufis, K.; Aboyans, V.; Desormais, I. 2018 Practice guidelines for the management of arterial hypertension of the european society of cardiology and the european society of hypertension. Blood Press., 2018, 27(6), 314-340.
[http://dx.doi.org/10.1080/08037051.2018.1527177] [PMID: 30380928]
[41]
Sheppard, J.P.; Stevens, S.; Stevens, R.; Martin, U.; Mant, J.; Hobbs, F.D.R.; McManus, R.J. Benefits and harms of antihypertensive treatment in low-risk patients with mild hypertension. JAMA Intern. Med., 2018, 178(12), 1626-1634.
[http://dx.doi.org/10.1001/jamainternmed.2018.4684] [PMID: 30383082]
[42]
Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, J.T., Jr; Roccella, E.J. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension, 2003, 42(6), 1206-1252.
[http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]
[43]
Messerli, F.H.; Bangalore, S.; Bavishi, C.; Rimoldi, S.F. Angiotensin-converting enzyme inhibitors in hypertension. J. Am. Coll. Cardiol., 2018, 71(13), 1474-1482.
[http://dx.doi.org/10.1016/j.jacc.2018.01.058] [PMID: 29598869]
[44]
Vučević, D.; Jorgačević, B.; Đorđević, D.; Radak, Đ.; Radosavljević, M.; Lalić, D. Diabetic vascular disease: Cellular and molecular approach. Medicinska istraživanja, 2017, 51(1), 18-28.
[45]
Radenkovic, M.; Stojanović, M.; Nešić, I.; Prostran, M. Angiotensin receptor blockers & endothelial dysfunction: Possible correlation & therapeutic implications. Indian J. Med. Res., 2016, 144(2), 154-168.
[http://dx.doi.org/10.4103/0971-5916.195022] [PMID: 27934794]
[46]
Gallo, G.; Volpe, M.; Rubattu, S. Angiotensin receptor blockers in the management of hypertension: A real-world perspective and current recommendations. Vasc. Health Risk Manag., 2022, 18, 507-515.
[http://dx.doi.org/10.2147/VHRM.S337640] [PMID: 35846737]
[47]
Rakugi, H.; Kario, K.; Yamaguchi, M.; Sasajima, T.; Gotou, H.; Zhang, J. Efficacy of sacubitril/valsartan versus olmesartan in Japanese patients with essential hypertension: A randomized, double-blind, multicenter study. Hypertens. Res., 2022, 45(5), 824-833.
[http://dx.doi.org/10.1038/s41440-021-00819-7] [PMID: 35058583]
[48]
Radenković, M.; Stojanović, M.; Prostran, M. Calcium channel blockers in restoration of endothelial function: systematic review and meta-analysis of randomized controlled trials. Curr. Med. Chem., 2019, 26(29), 5579-5595.
[http://dx.doi.org/10.2174/0929867325666180713144806] [PMID: 30009701]
[49]
World Health Organization. Guideline for the Pharmacological Treatment of Hypertension in Adults; World Health Organization: Genève, Switzerland, 2021, 48. https://www.who.int/publications/i/item/978924003- 3986
[50]
Roush, G.C.; Sica, D.A. Diuretics for hypertension: A review and update. Am. J. Hypertens., 2016, 29(10), 1130-1137.
[http://dx.doi.org/10.1093/ajh/hpw030] [PMID: 27048970]
[51]
Mishra, S. Diuretics in primary hypertension – Reloaded. Indian Heart J., 2016, 68(5), 720-723.
[http://dx.doi.org/10.1016/j.ihj.2016.08.013] [PMID: 27773415]
[52]
Jo, W.; Koh, E.S.; Chung, S. Therapeutic roles of thiazides and loop diuretics in blood pressure control and renal protection against chronic kidney disease. Clin. Hypertens., 2023, 29(1), 14.
[http://dx.doi.org/10.1186/s40885-023-00238-5] [PMID: 37183259]
[53]
Ruiz-Hurtado, G.; Banegas, J.R.; Sarafidis, P.A.; Volpe, M.; Williams, B.; Ruilope, L.M. Has the sprint trial introduced a new blood-pressure goal in hypertension? Nat. Rev. Cardiol., 2017, 14(9), 560-565.
[http://dx.doi.org/10.1038/nrcardio.2017.74] [PMID: 28492286]
[54]
Liew, D.; Krum, H. Aldosterone receptor antagonists for hypertension: What do they offer? Drugs, 2003, 63(19), 1963-1972.
[http://dx.doi.org/10.2165/00003495-200363190-00001] [PMID: 12962513]
[55]
Maron, B.A.; Leopold, J.A. Aldosterone receptor antagonists: Effective but often forgotten. Circulation, 2010, 121(7), 934-939.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.895235] [PMID: 20177008]
[56]
Guichard, J.L.; Clark, D., III; Calhoun, D.A.; Ahmed, M.I. Aldosterone receptor antagonists: Current perspectives and therapies. Vasc. Health Risk Manag., 2013, 9, 321-331.
[PMID: 23836977]
[57]
Wei, F.F.; Zhang, Z.Y.; Huang, Q.F.; Staessen, J.A. Diagnosis and management of resistant hypertension: State of the art. Nat. Rev. Nephrol., 2018, 14(7), 428-441.
[http://dx.doi.org/10.1038/s41581-018-0006-6] [PMID: 29700488]
[58]
Prichard, B.N.C.; Cruickshank, J.M.; Graham, B.R. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press., 2001, 10(5-6), 366-386.
[http://dx.doi.org/10.1080/080370501753400665] [PMID: 11822540]
[59]
Fowler, M.B. Hypertension, heart failure, and beta-adrenergic blocking drugs. J. Am. Coll. Cardiol., 2008, 52(13), 1073-1075.
[http://dx.doi.org/10.1016/j.jacc.2008.06.032] [PMID: 18848140]
[60]
Paštrović, F.; Okštajner, P.K.; Vodanović, M.; Raos, D.; Jug, J.; Lovrić Benčić, M.; Prkačin, I. The role of anxiolytics in hypertensive urgency management. Psychiatr. Danub., 2020, 32(4), 593-596.
[PMID: 33212468]
[61]
Radosavljevic, M.; Svob Strac, D.; Jancic, J.; Samardzic, J. The role of pharmacogenetics in personalizing the antidepressant and anxiolytic therapy. Genes, 2023, 14(5), 1095.
[http://dx.doi.org/10.3390/genes14051095] [PMID: 37239455]
[62]
Rahman, F.; Muthaiah, N.; Kumaramanickavel, G. Current concepts and molecular mechanisms in pharmacogenetics of essential hypertension. Indian J. Pharmacol., 2021, 53(4), 301-309.
[PMID: 34414909]
[63]
Lee, S.H.; Park, K.K.; Mah, S.Y.; Chung, B.H. Effects of α-blocker ‘add on’ treatment on blood pressure in symptomatic BPH with or without concomitant hypertension. Prostate Cancer Prostatic Dis., 2010, 13(4), 333-337.
[http://dx.doi.org/10.1038/pcan.2010.19] [PMID: 20567256]
[64]
Tziomalos, K.; Athyros, V.G.; Karagiannis, A.; Mikhailidis, D.P. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc. Med. J., 2011, 5(1), 85-89.
[http://dx.doi.org/10.2174/1874192401105010085] [PMID: 21769302]
[65]
van de Vusse, D.; Mian, P.; Schoenmakers, S.; Flint, R.B.; Visser, W.; Allegaert, K.; Versmissen, J. Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: A systematic review. Eur. J. Clin. Pharmacol., 2022, 78(11), 1763-1776.
[http://dx.doi.org/10.1007/s00228-022-03382-3] [PMID: 36104450]
[66]
Acelajado, M.C.; Hughes, Z.H.; Oparil, S.; Calhoun, D.A. Treatment of resistant and refractory hypertension. Circ. Res., 2019, 124(7), 1061-1070.
[http://dx.doi.org/10.1161/CIRCRESAHA.118.312156] [PMID: 30920924]
[67]
Shamon, S.D.; Perez, M.I. Blood pressure-lowering efficacy of reserpine for primary hypertension. Cochrane Libr., 2016, 2016(12), CD007655.
[http://dx.doi.org/10.1002/14651858.CD007655.pub3] [PMID: 27997978]
[68]
Sica, D.A. Minoxidil: An underused vasodilator for resistant or severe hypertension. J. Clin. Hypertens., 2004, 6(5), 283-287.
[http://dx.doi.org/10.1111/j.1524-6175.2004.03585.x] [PMID: 15133413]
[69]
Di Daniele, N.; De Francesco, M.; Violo, L.; Spinelli, A.; Simonetti, G. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol. Dial. Transplant., 2012, 27(4), 1689-1690.
[http://dx.doi.org/10.1093/ndt/gfs044] [PMID: 22467751]
[70]
Ipek, E.; Oktay, A.A.; Krim, S.R. Hypertensive crisis. Curr. Opin. Cardiol., 2017, 32(4), 397-406.
[http://dx.doi.org/10.1097/HCO.0000000000000398] [PMID: 28306673]
[71]
Patel, K.K.; Young, L.; Howell, E.H.; Hu, B.; Rutecki, G.; Thomas, G.; Rothberg, M.B. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JAMA Intern. Med., 2016, 176(7), 981-988.
[http://dx.doi.org/10.1001/jamainternmed.2016.1509] [PMID: 27294333]
[72]
Peixoto, A.J. Acute severe hypertension. N. Engl. J. Med., 2019, 381(19), 1843-1852.
[http://dx.doi.org/10.1056/NEJMcp1901117] [PMID: 31693807]
[73]
Paini, A.; Aggiusti, C.; Bertacchini, F.; Agabiti Rosei, C.; Maruelli, G.; Arnoldi, C.; Cappellini, S.; Muiesan, M.L.; Salvetti, M. Definitions and epidemiological aspects of hypertensive urgencies and emergencies. High Blood Press. Cardiovasc. Prev., 2018, 25(3), 241-244.
[http://dx.doi.org/10.1007/s40292-018-0263-2] [PMID: 29916180]
[74]
Kulkarni, S.; Glover, M.; Kapil, V.; Abrams, S.M.L.; Partridge, S.; McCormack, T.; Sever, P.; Delles, C.; Wilkinson, I.B. Management of hypertensive crisis: british and irish hypertension society position document. J. Hum. Hypertens., 2022, 37(10), 863-879.
[http://dx.doi.org/10.1038/s41371-022-00776-9] [PMID: 36418425]
[75]
Tisdale, J.E.; Huang, M.B.; Borzak, S. Risk factors for hypertensive crisis: Importance of out-patient blood pressure control. Fam. Pract., 2004, 21(4), 420-424.
[http://dx.doi.org/10.1093/fampra/cmh412] [PMID: 15249531]

Rights & Permissions Print Cite
Article Metrics
30
1
Wayfinder Image
Open Access Journals Promotions
World Antimicrobial Awareness Week
© 2024 Bentham Science Publishers | Privacy Policy